Extensive clinical and experimental studies conducted over the last few decades have provided convincing data indicating that high levels of COX-2 and PGE2 are implicated in the pathogenesis of colorectal carcinoma [13,14,15], and that they are associated with poorer survival outcomes [16]. This evidence concerns the gene PTGS2 and colorectal carcinoma.